Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016 Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
News
pfizer_building

5 things to know about the Pfizer/Allergan inversion collapse

April 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons

The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Feature
jj_sign_on_wall

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016 Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
News
allergan

Allergan, Pfizer confirm termination of $160 billion merger

April 6, 2016 Business Services, Research and Development, Sales and Marketing

Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
News
manufacturing

Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country

April 6, 2016 Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly

There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
News
celltrion

Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay

April 6, 2016 Manufacturing and Production, Research and Development

Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
News
pfizer_logo

Pfizer to call off $160 billion merger with Allergan

April 6, 2016 Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
News
trials

Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug

April 6, 2016 Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal

The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
News
mr058666-web

Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer

April 6, 2016 Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics

Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
News
figures_charts

Valeant’s ad hoc committee closes chapter on Philidor controversy

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee

Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
News
pfizerbrussels

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
News
clinical_trials_2

Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain

April 5, 2016 Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta

Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
News
descovy

FDA approves Gilead’s latest HIV treatment

April 5, 2016 Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
News
gilead-sciences

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026